Claudio Lotesoriere

8PUBLICATIONS
39CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Neurogenetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 26, 2025
Unravelling Paclitaxel Resistance in Gastric Cancer: The Role of Small Extracellular Vesicles in Epithelial Mesenchymal Transition and Extracellular Matrix Remodelling.

Giorgia Panzetta, Annalisa Schirizzi, Francesco Balestra

|Jan 08, 2025
Circulating miR-23b-3p, miR-30e-3p, and miR-205-5p as Novel Predictive Biomarkers for Ramucirumab-Paclitaxel Therapy Outcomes in Advanced Gastric Cancer.

Emanuele Piccinno, Annalisa Schirizzi, Viviana Scalavino

|Nov 22, 2024
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial.

Antonio Avallone, Francesco Giuliani, Alfonso De Stefano

|Jul 27, 2024
Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.

Carmelo Laface, Angela Dalia Ricci, Simona Vallarelli

|Feb 07, 2024
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).

Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile

|Oct 28, 2023
VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment.

Annalisa Schirizzi, Aram Arshadi, Doron Tolomeo

Pageof 2

Frequent Collaborators

4 joint publications

Gianluigi Giannelli

4 joint publications

Rosalba D'Alessandro

3 joint publications

Rossella Donghia

2 joint publications

Anna Maria Valentini